PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-36.86%
Negative ROE while Biotechnology median is -5.82%. Seth Klarman would investigate if capital structure or industry issues are at play.
80.34%
Positive ROA while Biotechnology median is negative. Philip Fisher would see if the firm has a stronger model than peers.
395.15%
Positive ROCE while Biotechnology median is negative. Peter Lynch might see a relative advantage over the sector.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.